Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma

Andrew B. Katims 1,*, Peter A. Reisz 1, Lucas Nogueira 1, Hong Truong 1, Andrew T. Lenis 1, Eugene J. Pietzak 1, Kwanghee Kim 2,* and Jonathan A. Coleman 1

1 Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
* Correspondence: katimsa@mskcc.org (A.B.K.); kimk1@mskcc.org (K.K.)

Simple Summary: Urothelial carcinoma is a malignancy of the cells lining the genitourinary tract but it most commonly occurs in the bladder. Once urothelial carcinoma has spread outside of the genitourinary tract, survival outcomes are poor despite the standard of care treatment of chemotherapy followed by immunotherapy. Genetic sequencing of cancer tissue has identified targets for new anti-cancer drugs. This review summarizes the evidence regarding the efficacy of targeted therapies in advanced urothelial carcinoma.

Abstract: This review describes the current landscape of targeted therapies in urothelial carcinoma. The standard of care for advanced urothelial carcinoma patients remains platinum-based combination chemotherapy followed by immunotherapy. However, median overall survival for these patients is still <1 year and there is an urgent need for alternative therapies. The advent of next-generation sequencing has allowed widespread comprehensive molecular characterization of urothelial tumors and, subsequently, the development of therapies targeting specific molecular pathways implicated in carcinogenesis such as FGFR inhibition, Nectin-4, Trop-2, and HER2 targeting. As these therapies are demonstrated to be effective in the second-line setting, they will be advanced in the treatment paradigm to localized and even non-muscle invasive disease.

Keywords: metastatic urothelial carcinoma; molecular targeted therapy; tumor biomarkers; antineoplastic therapy; monoclonal antibodies; antibody-drug conjugates; immunotherapy; next-generation sequencing

1. Introduction

Advanced and metastatic urothelial carcinoma (mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. In the mUC setting, prior to combination cisplatin-based chemotherapy, median survival was only approximately 4–6 months [1]. The development of cisplatin-based combination chemotherapy regimens increased median survival to 11–14.8 months with objective response rates (ORR) in the range of 40–49% [2–4]. While an improvement, relapse and progression are still very common in this disease and second line chemotherapies have demonstrated poor overall activity [5]. In addition, a significant portion (30–50%) of this patient population is cisplatin-ineligible due to renal insufficiency, poor performance status, hearing loss, neuropathy, or heart failure emphasizing the need for alternative, more efficacious therapies [6].

Over the last decade, accelerating basic science research has rendered a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Urothelial tumors were found to have a high mutational burden and to express high levels of programmed cell death ligand 1 (PD-L1), which when bound to its PD-1 receptor results in suppression of the T-cell-mediated antitumor
immune response allowing immune escape and tumor progression [7]. High PD-L1 expression has been strongly associated with a poor prognosis in urothelial carcinoma [8]. Antibodies designed to block this interaction and other immune checkpoint inhibitors (CPI) have demonstrated encouraging results in the second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. Phase III trials (NCT02302807, NCT00256436) of atezolizumab (Tecentriq®) and pembrolizumab (Keytruda®) in the second-line setting with an ORR of 20.3–23% and median OS 10.1–11.1 months led to Food and Drug Administration (FDA) approval of these immune checkpoint inhibitors starting in 2016 [9,10]. This was followed by approval of nivolumab (Opdivo®), durvalumab (Imfinzi®), and avelumab (Bavencio®) based on Phase I/II study data (NCT02387996, NCT01693562, NCT01772004) [11–13]. However, CPI as second-line therapy is still associated with a median overall survival <1 year. Consequently, multiple trials have been initiated evaluating combination regimens with dual CPI, CPI plus chemotherapy, or CPI plus alternative novel agents targeting specific molecular pathways [14,15]. This review will focus on these targeted therapies in advanced or metastatic urothelial cancer. We will discuss the molecular characterization of urothelial carcinoma that has led to identification of therapeutic targets. We will then review data from studies evaluating novel antibody and antibody-drug conjugates targeting pathways known to be critical in tumor development. Finally, we will discuss the limitations of tumor sequencing and targeted therapy and highlight opportunities for future research.

2. Next-Generation Sequencing Identifies Therapeutic Targets

Characterization of clinically relevant molecular pathways in urothelial carcinoma has been ongoing for many years but has exponentially accelerated with the advent of next-generation sequencing (NGS) and the completion of The Cancer Genome Atlas (TCGA) project providing a comprehensive profile of 131 high-grade muscle-invasive urothelial tumors of the bladder in 2014 [16]. Using whole exome sequencing (WES) with matched normal samples, 32 genes demonstrated significant levels of recurrent somatic mutation with TP53 pathway inactivation in 76% of the samples. Alterations affecting the PI3K/Akt/mTOR were found in 42% of samples and MAPK pathway alterations in 44% of samples [16]. In 2017, the TCGA published updated results from 412 muscle-invasive bladder cancers, identifying 58 significantly mutated genes (Figure 1) [17]. Subsequent sequencing studies have classified urothelial carcinoma into distinct molecular subtypes with differential prognoses and responses to conventional therapy [18]. Based on these large-scale molecular studies, targeted therapies have been developed and are just now demonstrating their efficacy in clinical trials (Table 1).

Figure 1. Mutational landscape of muscle-invasive urothelial carcinoma [17].
Table 1. Clinical data supporting the efficacy of targeted therapies in urothelial carcinoma.

| Reference | Agent | Trial | Phase | Setting | N | Biomarker | ORR | Median OS (months) | Primary Endpoint |
|-----------|-------|-------|-------|---------|---|-----------|-----|------------------|-----------------|
| Powles et al. Lancet 2018 [9] | atezolizumab vs. chemo | NCT02302807 | 3 | 2L mUC | 931 | PD-L1 (IC2/3) | 23.0% | 11.1 vs. 10.6 | OS |
| Bellmunt et al. NJEM 2017 [10] | pembrolizumab vs. chemo | NCT02256436 | 3 | 2L mUC | 542 | PD-L1 | 21.1% | 10.3 vs. 7.4 | OS, PFS |
| Loriot et al. NEJM 2019 [19] | erdafitinib | NCT02365597 | 2 | 2L mUC | 99 | FGFR3 | 40.0% | 13.8 | ORR |
| Pal et al. Cancer Discov 2018 [20] | infigratinib (BGJ398) | NCT01004224 | 1 | 2L mUC | 67 | FGFR3 | 25.4% | 7.75 | ORR |
| Schuler et al. Lancet Oncol 2019 [31] | rogartinib | NCT01976741 | 1 | 2L mUC | 52 | FGFR3 | 23.0% | NR | Safety |
| Sternberg et al. JCO 2022 [22] | enfortumab vedotin vs. chemo | NCT03410693 | 2/3 | 2L mUC | 175 | FGFR3 | 20.7% | 8.3 | ORR, OS |
| Powles et al. NEJM 2021 [23] | enfortumab vedotin vs. chemo | NCT03474107 | 3 | 2L mUC | 608 | Nectin-4 | 40.6% | 12.8 vs. 8.9 | OS |
| Rosenberg et al. [abstract] JCO 2020 [24] | enfortumab vedotin + pembro | NCT03288545 | 1b/2 | 1L cis-ineligible | 45 | Nectin-4/ PD-L1 | 73.3% | NR | Safety, ORR |
| Tagawa et al. JCO 2021 [35] | sacituzumab govitecan | NCT03547973 | 2 | 2L mUC | 113 | Trop-2 | 27.0% | 10.5 | ORR |
| Galsky et al. [abstract] JCO 2022 [36] | trastuzumab + nivolumab | NCT03523572 | 1b/2 | 2L mUC | 34 | HER2/PD-L1 | 36.7% | 11 | ORR |
| Bryce et al. [abstract] JCO 2017 [27] | trastuzumab + pertuzumab | NCT02091141 | 2 | 2L mUC | 12 | HER2 | 33.0% | NR | ORR |
| Sheng et al. Clin Cancer Res 2021 [28] | anti-HER2 RC48-ADC | NCT03507166 | 2 | 2L mUC | 43 | HER2 | 51.2% | 13.9 | ORR |
| Doi et al. Oncologist 2020 [29] | bintrafusp alfa | NCT02699515 | 1 | 2L solid tumors | 23 | TGF-Beta/ PD-L1 | 14.3% | NR | Safety |
| Strauss et al. Clin Cancer Res 2018 [30] | bintrafusp alfa | NCT02517398 | 1 | 2L solid tumors | 19 | TGF-Beta/ PD-L1 | 26.5% | NR | Safety |
| Tomczak et al. [abstract] JCO 2021 [31] | eganelisib + nivolumab | NCT03980041 | 2 | 2L mUC | 49 | PI3K-γ | 30.3% | NR | ORR |
| Kim et al. [abstract] JCO 2021 [32] | sapanisertib | NCT03047213 | 2 | 2L mUC | 17 | mTORC1/2 | 0.0% | 3.4 | ORR |

Several transcriptomic studies have further characterized the heterogeneity of mUC and have allowed for more accurate molecular characterization which has improved prognostic stratification and improved targeted therapeutic options. In 2020, Kamoun et al. reconciled 18 datasets to derive a consensus molecular classification consisting of 6 distinct molecular subtypes which were labelled as luminal papillary (LumP), luminal nonspecified (LumNS), luminal unstable (LumU), stroma-rich, basal/squamous (Ba/Sq), and neuroendocrine-like (NE-like). Each subtype has a distinct clinical, histologic, mutational, survival, and stromal/immune infiltrate as summarized in Figure 2 [18]. While these subtypes are critical to characterizing tumors and targeting therapies, it is important to note that the differences in intertumoral heterogeneity do not necessarily reflect differences in intratumor heterogeneity and there are many overlapping signaling pathways that
can be targeted (Figure 3). In each subsequent section, we will highlight the molecular classification associated with each targeted therapy.

| Class Name               | Differentiation | Oncogenic mechanisms | Mutations | Stromal infiltrate | Immune infiltrate | Histology                       | Clinical        | Median overall survival (years) |
|--------------------------|-----------------|----------------------|-----------|--------------------|-------------------|---------------------------------|-----------------|---------------------------------|
| Luminal Papillary (LumP) | Urothelial / Luminal | FGFR3 + PPARG + CDKN2A- | FGFR3 (40%), KDM6A (38%) | Fibroblasts | Papillary morphology (59%) | T2 stage + | 4 |                           |
| Luminal Non-Specified (LumNS) |                 | PPARG +               | ELF3 (35%) | Micropapillary variant (36%) | B cells | Older patients (BO+) | 1.8 |                           |
| Luminal Unstable (LumU)  |                 | PPARG + E2F3 + ERBB2 + Genomic instability | TPS3 (76%), ERCC2 (22%) | Myofibroblasts | Squamous differentiation (42%) | Women + T3/T4 stage + | 2.9 |                           |
| Stroma-rich              |                 | EGFR +                |           | Smooth muscle Fibroblasts | CDS T cells | CDS T cells, NK cells | 3.8 |                           |
| BasalSquamous (BaSq)     | Basal            | TP53, RB1, Cell cycle |           | Fibroblasts Myofibroblasts | B cells | Squamous differentiation (72%) | 1.2 |                           |
| Neuroendocrine-like (NE-like) | Neuroendocrine   | TP53 (84%), RB1 (39%)* |           | Smooth muscle Fibroblasts | CD8 T cells | Neuroendocrine differentiation (72%) | 1 |                           |

* 94% of these tumors present either Rb1 mutation or deletion

Figure 2. Summary of consensus classes and their unique features [18].

![Figure 3. Overview of cell signaling pathway and targets of novel therapy. Created with BioRender.com (accessed on 18 October 2022).](image-url)
3. Fibroblast Growth Factor Receptor (FGFR) Inhibition

The FGFR signaling pathway is involved in cell proliferation, differentiation, angiogenesis, metabolism, mobility, and invasion. Five FGF receptors have been identified (FGFR1-5). Cell signaling is propagated via a tyrosine kinase signaling pathway. Activation of FGFR causes four main downstream cascades which include RAS/Raf/MEK-MAPK, PI3K/AKT, PLC-gamma, and signal transducer and activation of transcription (STAT) [33,34]. FGFR alterations have been identified most commonly in urothelial carcinoma and intrahepatic cholangiocarcinoma.

FGFR3 alterations are particularly common in urothelial cancer and have been noted in 12–18% of urothelial tumors and are generally associated with lower grade and lower stage tumors. However, up to 20% of advanced urothelial carcinoma and 37% of upper tract urothelial carcinoma (UTUC) demonstrate FGFR3 alterations. FGFR3 alterations have been associated with the LumP subtype and a T-cell-depleted immune phenotype in bladder cancer which may contribute to a poor response to CPI [35,36]. Of note, the LumP subtype is associated with the best median overall survival (4 years) and a papillary architecture. Both FGFR3-specific and pan-FGFR inhibitors have been developed with variable activity. Erdafitinib (Balversa®), a tyrosine kinase (TKI) FGFR1-4 inhibitor, demonstrated anti-tumor activity in preclinical models as well as a Phase I trial (NCT01703481) in patients with known somatic FGFR3 alterations for patients with mUC or intrahepatic cholangiocarcinoma. There was a 46% response rate in UC and a 27% response rate in patients with cholangiocarcinoma [37]. This led to a Phase II trial (NCT02365597) and FDA approval of the use of erdafitinib for FGFR2/3-altered platinum-treated mUC patients with an ORR of 40% and median OS of 13.8 months. The most common side effects included: hyperphosphatemia (77%), stomatitis (58%), and diarrhea (51%). Among the 67% of grade 3 or 4 events, 46% were considered to be treatment related and consisted of hyponatremia (11%), stomatitis (10%), and asthenia (7%) [19]. Erdafitinib also has FDA approval in the setting of locally advanced, unresectable, or metastatic cholangiocarcinoma and known FGFR2 mutations. Infigratinib (Truseltiq®), a selective inhibitor of FGFR1-3, was originally developed to treat FGFR2-mutated advanced cholangiocarcinoma but has demonstrated activity in small prospective trials in previously treated FGFR-altered mUC with an ORR of 25.3% and a notably higher ORR of 50% in a subset of eight patients with UTUC [20,38]. A Phase III trial (NCT04197986) is planned for mUC, and a Phase I trial is recruiting for treatment of high-grade glioma (NCT04429466). Rogaratinib is a potent small molecule inhibitor of FGFR1-4 kinase activity whose activity has been strongly correlated to high tumor FGFR mRNA expression, with mRNA expression used as an alternative and potentially more specific biomarker in a Phase I study (NCT01976741). This study included 52 patients with urothelial carcinoma with an ORR of 23%. Other solid tumors with high levels of FGFR expression were included in this study, such as non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and cholangiocarcinoma, but none had as robust a response compared to urothelial carcinoma [21]. An ongoing Phase II/III trial (NCT03410693) recently published unplanned interim analysis results which compared Rogaratinib to chemotherapy (docetaxel, paclitaxel, or vinflunine). The ORR was 20.7% for the Rogaratinib group vs. 19.3% for the chemotherapy group. Because of the similar efficacy, the trial was stopped prior to progression to Phase III [22]. While better tolerated than cytotoxic chemotherapy, FGFR3 inhibitors are not without adverse events, the most common being hyperphosphatemia, diarrhea, fatigue, central serous retinopathy, stomatitis, and nail/skin disorders [39]. FGFR3 inhibition serves as a pivotal and first step in the approval of targeted therapies in urothelial cancers based on the unique molecular alterations present in an individual tumor. It is noteworthy that the activation signatures associated with the LumP subtype suggest that these tumors may respond to FGFR inhibition regardless of their FGFR3 mutational status [17,40].
4. Nectin-4 Targeting

Nectin-4 is an immunoglobulin-like adhesion molecule that acts as a tumor antigen that is overexpressed in most epithelial cancers, including urothelial carcinomas [41]. Nectin-4 has been shown to promote cancer cell proliferation and metastasis through activation of the PI3K-AKT signaling pathway. Additionally, there is interaction with ERBB2, a tyrosine kinase which activates PI3K-AKT, which has important therapeutic implications, which will be discussed in a later section [42]. Enfortumab vedotin (EV) (Padcev®) is an antibody-drug conjugate (ADC) with a human anti-nectin-4 antibody linked to monomethyl auristatin E, which has cytotoxic activity via microtubule disruption. In 2019, EV was approved by the FDA based on results from a Phase I trial (NCT02091999) in mUC patients previously treated with chemotherapy that demonstrated an ORR of 43% and a median OS of 12.3 months. This efficacy was further supported by the recently published Phase III data (NCT03474107) from the EV-301 trial of EV versus chemotherapy demonstrating an ORR of 40.6% vs. 17.9% and a median OS 12.8 vs. 8.9 months, respectively [23]. Treatment-related adverse events (TRAE) were common, with 51.4% of the EV group experiencing a grade 3 or higher TRAE. The most common adverse events were maculopapular rash, fatigue, and neutropenia [23]. Notably, Nectin-4 expression is considered widespread enough that no biomarker testing is needed prior to treatment. However, recent analysis of Nectin-4 expression across molecular subtypes demonstrated heterogeneity with significant enrichment of Nectin-4 expression in luminal subtypes (LumP, LumNS, LumU) and they had a positive correlation with luminal subtype molecular drivers such as GATA3, PPARG, and FOXA1 [43]. More research is needed to assess if patients harboring non-luminal subtypes show equal benefit to EV compared to the luminal counterparts. EV is not approved for any other malignancy at this time.

Combination therapy of EV with pembrolizumab, a PD1 receptor inhibitor, in the Phase Ib/II EV-103 trial (NCT03288545) has demonstrated promising results with an ORR of 73.3% in a heavily pre-treated population with one third of patients having liver metastases [24]. Combination therapy with EV plus pembrolizumab is also being investigated in the peri-operative setting in EV-303, a Phase II study (NCT03924895) [44].

5. Trophoblast Cell Surface Antigen 2 (Trop-2) Targeting

Trop-2 is a transmembrane protein that has been shown to be overexpressed in urothelial carcinoma, acting as a tumor antigen. Activation of Trop-2 increases intracellular calcium stores, which activates MAPK signaling, as well as the NF-KB and RAF pathways [45]. Sacituzumab govitecan (SG) (Trodelvy®) is an ADC consisting of an anti-Trop-2 antibody linked to SN-38 which is the active metabolite of irinotecan [45]. SG demonstrated efficacy in metastatic triple negative breast cancer, NSCLC, and urothelial cancer [46]. The TROPiCS-04 comparing SG versus single-agent chemotherapy treatment of choice is currently enrolling [25]. The most significant toxicity associated with SG is myelosuppression, along with alopecia, and diarrhea [46]. Neoadjuvant SG with or without pembrolizumab prior to radical cystectomy is under investigation in the Phase II SURE trial (NCT05226117) [47]. Originally, SG received FDA approval for treatment of metastatic triple negative breast cancer. Subsequently, on 13 April 2021, the FDA granted accelerated approval for SG for patients with mUC previously treated with platinum-based chemotherapy or immunotherapy and it was also fast-tracked for treatment of NSCLC. Furthermore, a recent analysis found high Trop-2 expression in all molecular subtypes except neuroendocrine. Tumor cells retained expression of Trop-2 even after prolonged exposure to EV, suggesting feasibility of a second line treatment with SG after EV [48].

6. Human Epidermal Growth Factor 2 (HER2) Targeting

HER2 (encoded by gene ERBB2) is a non-ligand binding member of the human epidermal growth factor receptor family of receptor tyrosine kinase involved in the mitogen-
activated protein kinase (MAPK) signaling pathway. NGS has demonstrated high rates of ERBB gene alterations and HER2 overexpression in urothelial carcinoma [17,49]. The ERBB family consists of EGFR, HER2 (ERBB2), ERBB3, and ERBB4. HER2 expression is most commonly seen in the luminal subtype and EGFR expression is seen more commonly in the basal/squamous subtype. Initial small trials using HER2 directed therapies in mUC have demonstrated mixed results. Afatinib (Gilotrif®, Giotrif®, Afanix®), an oral irreversible inhibitor of the ERBB family originally approved for EGFR-altered NSCLC patients, was studied in a Phase II trial (NCT02122172) in platinum-refractory mUC and demonstrated some efficacy in PFS at 3 months, with five of the six patients with HER2 and ERBB3 alterations meeting the endpoint [50]. Afatinib has also shown some activity against HNSCC and metastatic breast cancer but has not yet received FDA approval. Trastuzumab (Herceptin®, Ogivri®, Herzuma®), an anti-HER2 monoclonal Ab, was originally developed for HER2+ metastatic breast cancer but has subsequently been approved for gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. A Phase II study (NCT02091141) evaluated the efficacy of trastuzumab plus pertuzumab (Perjeta®), an anti-HER2 monoclonal Ab with complementary binding kinetics used in HER2+ breast cancer, in previously treated mUC with an ORR of 33% in those with HER2 overexpression [27]. However, use of HER2-targeted ADCs, such as RC48-ADC, has demonstrated some promise, demonstrating an ORR of 51.2% in previously treated patients with mUC, with an ORR of 60% in a subgroup of patients with higher HER2 expression (NCT03507166) [28]. Toxicity was low, with leukopenia, hypoesthesia, and alopecia being most common [28]. Trastuzumab linked to deruxtecan (Enhertu®), a topoisomerase I inhibitor, is another ADC with similar indications to trastuzumab monotherapy and is currently being tested in combination with nivolumab (NCT03523572). Preliminary results reveal an ORR of 36.7% with a median OS of 11 months. The safety profile was similar to those treated with trastuzumab deruxtecan alone, with interstitial lung disease/pneumonitis occurring in 23.5% of all participants [26]. SGNTUC-019 is an ongoing Phase II basket trial (NCT04579380) with dual targeting of HER2 with tucatinib (Tukysa®), a HER2 kinase inhibitor also used in the treatment of HER2+ breast cancer, and trastuzumab in patients with previously treated solid tumors, including urothelial carcinoma [51].

7. Transforming Growth Factor Beta (TGF-β) Inhibition

TGF-β is a cytokine that can act to suppress the host immune response to tumor formation and contribute to anti-PD-L1 resistance in mUC by excluding CD8 T cells from the tumor [52]. There is also evidence that TGF-β plays a role in regulating the epithelial–mesenchymal transition (EMT) of cancer cells, which is associated with invasion and therapy resistance [53]. Preclinical studies of TGF-β inhibition demonstrated improved anti-tumor immunity; however single agent anti-TGF-β therapy alone has not been very successful. Bintrafusp alfa (BA) is a first-in-class bifunctional anti-PD-L1/TGF-β receptor II fusion protein designed to inhibit PD-L1-mediated immunosuppression as well as TGF-β levels in the tumor microenvironment. Preclinical data demonstrated that BA resulted in improved antitumor activity vs. TGF-β or PD-L1 monotherapy alone and was able to both prevent EMT as well as revert cells that had already undergone EMT in multiple solid tumor types [53]. Two Phase I trials (NCT02699515, NCT02517398) in solid tumors demonstrated an ORR of 14.3–26.5% with a tolerable toxicity profile [29,30]. A urothelial-specific Phase Ib trial (NCT04349280) is ongoing in previously platinum-treated mUC patients with the goal of enrolling 40 patients [54]. However, a Phase II trial (NCT04501094) in patients with metastatic, refractory urothelial carcinoma was terminated due to low accrual. Trials involving BA have lacked improved efficacy over established therapies which may halt future development.
8. Phosphoinositide-3-Kinase (PI3K) Inhibition

The PI3K pathway is upstream of the protein kinase B (Akt) and mammalian target of rapamycin (mTOR) pathways, with PIK3CA mutations and subsequent upregulation of the PI3K pathway common in urothelial carcinoma. The PI3K pathway is activated due to multiple different mutations as previously discussed, and because of its ubiquity, regulation of apoptosis, and multiple downstream targets, we will review the signaling pathway in greater depth.

PI3K is activated by extracellular signals (i.e., FGFR, EGFR, receptor tyrosine kinase, etc.) which leads to autophosphorylation and activation of Akt through PIP2 to PIP3 conversion. Activation of Akt leads to several events. Primarily, mTOR is upregulated which in turn increases cell growth, protein synthesis, and energy storage. There is a further direct effect on NF-KB. Phosphorylation of Xiap leads to inhibition of MDM2 and subsequent activation of p53 which blocks autophagy. There is also activation of PAK1 which has inhibitory effects on apoptosis. Ultimately, these events lead to cancer cell resistance (anti-apoptosis), cell cycle progression, and cell proliferation. The primary inhibitor of this pathway is the tumor suppressor, PTEN [55]. Further evidence suggests that PI3K serves as a gatekeeper, preventing excessive innate immune response [56].

It is thought that PIK3CA mutations are an early genetic alteration in urothelial carcinogenesis and are associated with FGFR3 mutations [57]. Eganelsib is a novel oral inhibitor of the PI3K-gamma subunit evaluated in a Phase II study (NCT03980041) in combination with nivolumab with an ORR of 30% in platinum-treated mUC. Because of the effect on the immune response, eganelisib is designed to increase the efficacy of nivolumab. Notably PD-L1+ patients demonstrated an ORR of 80%, although this was in a small subset of five patients [31]. Eganelsib is currently FDA approved for the treatment of triple negative breast cancer.

9. Mammalian Target of Rapamycin (mTOR) Inhibition

The mTOR pathway is downstream from the PI3K and Akt pathways. The mTOR pathway consists of mTORC1 or mTORC2 which are kinases involved in cell cycle regulation as well as angiogenesis via hypoxia-inducible factor-1 (HIF-1) and they act via the tuberous sclerosis complex 1 and 2 (TSC1/TSC2) GPTase activating protein (GAP). Everolimus (Zortress®, Afinitor®, Disperz®), an oral mTORC1 inhibitor currently used to treat advanced renal cell carcinoma, HR+ HER2− breast cancer, neuroendocrine tumors, and tumors associated with tuberous sclerosis, was evaluated in a Phase II trial (NCT00805129) in platinum-treated mUC with an ORR of only 5%, although patients with TSC1-mutant tumors demonstrated a significantly better response [58,59]. Based on this finding, several additional Phase II trials (NCT01827943) using mTOR inhibitor monotherapy were initiated but have not yielded encouraging results to date [60]. Buparlisib, originally developed for HER2- breast cancer but abandoned due to high toxicity and suboptimal results, is a panisoform class I PI3K inhibitor evaluated in a Phase II study (NCT01551030) of 13 patients but it did not meet its primary endpoints even in TSC1-altered patients and was associated with significant toxicity and currently has no FDA approvals [61]. Sapanisertib is a potent inhibitor of mTORC1 and 2 and was recently evaluated in a Phase II trial (NCT03047213) in 17 patients with TSC1/TSC2-mutated mUC, but the trial was terminated for futility, and it was suggested that further studies should evaluate molecular alterations beyond TSC1/2 [32]. Sapanisertib is currently under investigation in multiple solid tumor types with no current FDA approvals. Combination therapy with TKIs, CPI, and mTOR inhibitors have been more promising, with multiple trials ongoing [62]. Treatment with TKIs is not without adverse events and many trials must limit dosing or end accrual early due to intolerable side effects such as edema, hypothyroidism, nausea, vomiting and diarrhea [63].
10. Limitations of Targeted Therapy

Despite the excitement surrounding targeted therapies, there remain significant limitations to their success. The first is intratumoral and temporal heterogeneity. Urothelial tumors are generally genetically unstable and heterogeneous in their clonal makeup [7]. A therapy that targets an alteration in one clone may be ineffective against others or even accelerate their growth by applying selective pressure. Similarly, metastatic or recurrent disease may have different somatic alterations than the primary with differential treatment response. Biomarkers derived from bulk sequencing or immunohistochemistry (IHC) of one biopsy may not be representative of the remainder of the disease burden. Combination therapy with cytotoxic agents, CPI, and targeted therapies seeks to combat treatment resistance driven by the selective pressure of monotherapies.

Another significant limitation is the cost and availability of NGS. Despite an exponential decrease in the cost and speed of sequencing, routine sequencing of cancer tissue has not yet gained traction in clinical practice [64]. Cancer care delivery is highly fragmented, and resources vary depending on geography. The institutional investment required to establish a clinical genomics program is high, including equipment, reagents, personnel, and an analytics team. There are commercial assays available, but they vary in expense, coverage, and targets identified. Protocols for specimen handling, storage, and transport can be complex and labor-intensive. We expect that in the future, routine NGS will be commonplace, but there remain many systemic barriers.

On the horizon, there is an increasing role for single cell and spatial transcriptomics/proteomics along with computational methods to more comprehensively characterize tumors and their immune microenvironment to identify reliable and predictive biomarkers. These new technologies, while powerful, are currently cost prohibitive for use outside of the research setting and limited to highly specialized centers.

11. Conclusions

The advent of NGS has accelerated our ability to accurately characterize the molecular biology of urothelial carcinoma, allowing identification of distinct molecular subgroup classification, carcinogenic targets, and rapid iteration of potential therapeutic compounds. The standard of care remains platinum-based chemotherapy followed by maintenance immunotherapy or immunotherapy alone in platinum-ineligible patients. However, the relatively dismal prognosis of mUC and large proportion of platinum-ineligible patients emphasize the urgent and unmet need for additional therapies. The therapies reviewed above are promising both in the second line setting and in combination with CPI or chemotherapy. As these therapies are demonstrated to be efficacious in the metastatic setting, new trials have begun advancing these targeted therapies earlier in the treatment paradigm to the localized, neoadjuvant, and even non-muscle invasive setting.

Molecular characterization based on transcriptomic profiling has allowed for the identification of six distinct, clinically relevant consensus classes. Though there are unique transcriptomic signatures of each class, there is significant overlap in cell signaling pathways which may be targeted at various steps. Alterations leading to activation of the PI3K/AKT pathway are common among all luminal types and the Ba/Sq subtype. Yet, there is more to be explored from consensus classification. For example, NE-like and LumU tumors have expression profiles suggesting sensitivity to radiotherapy, and Ba/Sq appears to be sensitive to EGFR targeted therapies in pre-clinical models. These avenues are yet to be studied robustly in a clinical trial. Further complicating matters are intratumor heterogeneity and the tumor immune microenvironment regulating responses to specific targeted therapies.

Taken together, there is optimism that adoption of widespread molecular profiling, targeted therapies alone or in combination, and increased clinical trial availability and enrollment will result in meaningful improvements in survival for patients with urothelial carcinoma.
Author Contributions: All authors contributed significantly to this work and can be credited with the following. Conceptualization: P.A.R., K.K., J.A.C.; data curation: A.B.K., P.A.R., L.N.; investigation: A.B.K., P.A.R., L.N.; supervision: E.J.P., K.K., J.A.C.; validation: H.T., A.T.L.; visualization: A.B.K., P.A.R.; writing—original draft: A.B.K. and P.A.R.; writing—review and editing: all authors. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Yagoda, A. Chemotherapy of Urothelial Tract Tumors. Cancer 1987, 60, 574–585. [CrossRef]
2. Sternberg, C.N.; De Mulder, P.H.; Schornagel, J.H.; Théodore, C.; Fossa, S.D.; Van Oosterom, A.T.; Witjes, F.; Spina, M.; Van Groeningen, C.J.; De Balincourt, C.; et al. Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J. Clin. Oncol. 2001, 19, 2638–2646. [CrossRef]
3. Von Der Maase, H.; Hansen, S.W.; Roberts, J.T.; Dogliotti, L.; Oliver, T.; Moore, M.J.; Bodrog, I.; Albers, P.; Knuth, A.; Lippert, C.M.; et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. J. Clin. Oncol. 2000, 18, 3068–3077. [CrossRef]
4. Von Der Maase, H.; Sengelov, L.; Roberts, J.T.; Ricci, S.; Dogliotti, L.; Oliver, T.; Moore, M.J.; Zimmermann, A.; Arning, M. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients with Bladder Cancer. J. Clin. Oncol. 2005, 23, 4602–4608. [CrossRef]
5. Seront, E.; Machiels, J.-P. Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treat. Rev. 2015, 41, 341–353. [CrossRef]
6. Dash, A.; Galsky, M.D.; Vickers, A.J.; Ms, A.M.S.; Koppie, T.M.; Dalbagni, G.; Bochner, B.H. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006, 107, 506–513. [CrossRef]
7. Alexandrov, L.B.; Nik-Zainal, S.; Wedge, D.C.; Aparicio, S.A.J.R.; Behjati, S.; Biankin, A.V.; Bignell, G.R.; Bolli, N.; Borg, A.; Berresen-Dale, A.-L.; et al. Signatures of mutational processes in human cancer. Nature 2013, 500, 415–421. [CrossRef] [PubMed]
8. Van Wilpe, S.; Gerretsen, E.C.F.; Van Der Heijden, A.G.; De Vries, I.J.M.; Gerritsen, W.R.; Mehra, N. Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder. Cancers 2020, 12, 2692. [CrossRef]
9. Powles, T.; Durán, I.; Van Der Heijden, M.S.; Loriot, Y.; Vogelzang, N.J.; De Giorgi, U.; Oudard, S.; Retz, M.M.; Castellano, D.; Biamis, A.; et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018, 391, 748–757. [CrossRef]
10. Bellmunt, J.; De Wit, R.; Vaughn, D.J.; Fradet, Y.; Lee, J.-L.; Fong, L.; Vogelzang, N.J.; Climent, M.A.; Petrylak, D.P.; Choueiri, T.K.; et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N. Engl. J. Med. 2017, 376, 1015–1026. [CrossRef]
11. Sharma, P.; Retz, M.; Siefker-Radtke, A.; Baron, A.; Necchi, A.; Bedke, J.; Pлимак, E.R.; Vaena, D.; Grimm, M.-O.; Bracarda, S.; et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017, 18, 312–322. [CrossRef]
12. Powles, T.; O’Donnell, P.H.; Massard, C.; Arkenau, H.-T.; Friedlander, T.W.; Hoimes, C.; Lee, J.L.; Ong, M.; Sridhar, S.S.; Vogelzang, N.J.; et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Up-dated Results From A Phase 1/2 Open-Label Study. JAMA Oncol. 2017, 3, e172411. [CrossRef] [PubMed]
13. Apolo, A.B.; Infante, J.R.; Balmanoukian, A.; Patel, M.R.; Wang, D.; Kelly, K.; Mega, A.E.; Britten, C.D.; Ravaud, A.; Mita, A.C.; et al. Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients with Refractory Metastatic Urothelial Carcinoma: Results from a Multicenter, Phase Ib Study. J. Clin. Oncol. 2017, 35, 2117–2124. [CrossRef] [PubMed]
14. Powles, T.; van der Heijden, M.S.; Castellano, D.; Galsky, M.D.; Loriot, Y.; Petrylak, D.P.; Ogawa, O.; Park, S.H.; Lee, J.-L.; De Giorgi, U.; et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020, 21, 1574–1588. [CrossRef]
15. Teo, M.Y.; Iyer, G. The landscape of immunotherapy in metastatic urothelial carcinoma. Curr. Opin. Urol. 2019, 29, 643–648. [CrossRef]
16. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507, 315–322. [CrossRef] [PubMed]
17. Robertson, A.G.; Kim, J.; Al-Ahmadie, H.; Bellmunt, J.; Guo, G.; Charniack, A.D.; Hinoue, T.; Laird, P.W.; Hoadley, K.A.; Akbani, R.; et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 2017, 171, 540–556.e25. [CrossRef] [PubMed]
18. Kamoun, A.; de Reynies, A.; Allory, Y.; Spådahl, G.; Robertson, A.G.; Seiler, R.; Hoadley, K.A.; Groeneveld, C.S.; Al-Ahmadie, H.; Choi, W.; et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur. Urol. 2020, 77, 420–433. [CrossRef] [PubMed]
19. Loriot, Y.; Necchi, A.; Park, S.H.; Garcia-Donas, J.; Huddart, R.; Burgess, E.; Fleming, M.; Rezazadeh, A.; Mellado, B.; Varlamov, S.; et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. *N. Engl. J. Med.* 2019, 381, 338–348. [CrossRef]

20. Pal, S.K.; Rosenberg, J.E.; Hoffman-Censits, J.H.; Berger, R.; Quinn, D.I.; Galsky, M.D.; Wolf, J.; Dittrich, C.; Keam, B.; Delord, J.-P.; et al. Efficacy of BC11938, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. *Cancer Discov.* 2018, 8, 812–821. [CrossRef]

21. Schuler, M.; Cho, B.C.; Sayehlil, C.M.; Navarro, A.; Soo, R.A.; Richly, H.; Cassier, P.A.; Tai, D.; Penel, N.; Nogova, L.; et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: A phase 1 dose-escalation and dose-expansion study. *Lancet Oncol.* 2019, 20, 1454–1466. [CrossRef]

22. Sternberg, C.N.; Petrylak, D.P.; Bellmunt, J.; Nishiyama, H.; Necchi, A.; Gurney, H.; Lee, J.-L.; van der Heijden, M.S.; Rosenbaum, E.; Penel, N.; et al. FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. *J. Clin. Oncol.* 2022. [CrossRef] [PubMed]

23. Powles, T.; Rosenberg, J.E.; Sonpavde, G.P.; Loriot, Y.; Durán, I.; Lee, J.-L.; Matsusbara, N.; Vulteke, C.; Castellano, D.; Wu, C.; et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. *N. Engl. J. Med.* 2021, 384, 1125–1135. [CrossRef]

24. Rosenberg, J.E.; Flagg, T.W.; Friedlander, T.W.; Milowsky, M.I.; Srivinas, S.; Petrylak, D.P.; Merchant, J.R.; Bilen, M.A.; Carret, A.; Yuan, N.; et al. Study Ev-103: Preliminary Durability Results of Enfortumab Vedotin Plus Pembrolizumab for Locally Dvanced Or Metastatic Urothelial Carcinoma. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2020, 38, 441. [CrossRef]

25. Grivas, P.; Tagawa, S.T.; Bellmunt, J.; de Santis, M.; Duran, I.; Goebell, P.; necchi, A.; Stridhar, S.S.; Sternberg, C.N.; Aziz, M.U.; et al. Tropics-04: Study of Sactizumab Govitecan in Metastatic or Locally Advanced Unresectable Urothelial Cancer That Has progressed After Platinum and Checkpoint Inhibitor Therapy. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2021, 39, TPS498. [CrossRef] [PubMed]

26. Galsky, M.D.; Del Conte, G.; Foti, S.; Yu, E.Y.; Machiels, J.-P.H.; Doger, B.; Necchi, A.; De Braud, F.G.; Hamilton, E.P.; Hennequin, B.; et al. Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC). *J. Clin. Oncol.* 2022, 40, 438. [CrossRef]

27. Bryce, A.H.; Kurzrock, R.; Mercier-Bernstam, F.; Hurwitz, H.; Hainsworth, J.D.; Spigel, D.R.; Bose, R.; Swanton, C.; Burris, H.A.; Guo, S.; et al. Pertuzumab plus trastuzumab for trastuzumab-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway. *J. Clin. Oncol.* 2017, 35, 343. [CrossRef]

28. Sheng, X.; Zhou, A.-P.; Yao, X.; Shi, Y.; Luo, H.; Shi, B.; Liu, J.; Yu, G.; He, Z.; Hu, C.; et al. A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma. *J. Clin. Oncol.* 2019, 37, 4509. [CrossRef]

29. Doi, T.; Fujiwara, Y.; Koyama, T.; Ikeda, M.; Helwig, C.; Watanabe, M.; Vugmeyster, Y.; Kudo, M. Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort. *Oncologist* 2020, 25, e1292–e1302. [CrossRef]

30. Strauss, J.; Heery, C.R.; Schlom, J.; Madan, R.A.; Cao, L.; Kang, Z.; Lamping, E.; Marté, J.L.; Donahue, R.N.; Grenga, L.; et al. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors. *Clin. Cancer Res.* 2018, 24, 1287–1295. [CrossRef] [PubMed]

31. Tomczak, P.; Popovic, L.; Barthelemy, P.; Janicic, A.; Fernandez, E.S.; Borchelli, D.; Aglietta, M.; Maroto, J.; Carnot, A.; O’Connell, B.; et al. Preliminary analysis of a phase ii, multicenter, randomized, active-control study to evaluate the efficacy and safety of eglanisib (IPI 549) in combination with nivolumab monotherapy in patients with advanced urothelial carcinoma. *J. Clin. Oncol.* 2021, 39, 436. [CrossRef] [PubMed]

32. Kim, J.W.; Milowsky, M.I.; Hahn, N.M.; Kwiatkowski, D.J.; Morgans, A.K.; Davis, N.B.; Appleman, L.J.; Gupta, S.; Lara, P.N.; Hoffman-Censits, J.H.; et al. Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2-mutated metastatic urothelial carcinoma that progressed after platinum and checkpoint inhibitor therapy. *Cancers* 2022, 14, 5431. [CrossRef]

33. Xiao, J.-F.; Caliri, A.W.; Duex, J.E.; Theodorescu, D. Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling. *Cancers* 2021, 13, 4891. [CrossRef] [PubMed]

34. Sweis, R.F.; Spranger, S.; Bao, R.; Paner, G.P.; Stadler, W.M.; Steinberg, G.; Gajewski, T.F. Molecular Drivers of the Non–T-Cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. *Cancer Immunol. Res.* 2016, 4, 563–568. [CrossRef] [PubMed]

35. Kacew, A.; Sweis, R.F. FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. *Front. Immunol.* 2020, 11, 57528. [CrossRef] [PubMed]

36. Bahleda, R.; Italiano, A.; Hierro, C.; Mita, A.; Cervantes, A.; Chan, N.; Awad, M.; Calvo, E.; Moreno, V.; Govindan, R.; et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. *Clin. Cancer Res.* 2019, 25, 4888–4897. [CrossRef]

37. Pal, S.K.; Bajorin, D.; Dizman, N.; Hoffman-Censits, J.; Quinn, D.I.; Petrylak, D.P.; Galsky, M.D.; Vaishampayan, U.; De Giorgi, U.; Gupta, S.; et al. Infrafatinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. *Cancer* 2020, 126, 2597–2606. [CrossRef] [PubMed]

38. Siefker-Radtke, A.O.; Necchi, A.; Park, S.H.; Garcia-Donas, J.; Huddart, R.; Burgess, E.F.; Fleming, M.T.; Rezazadeh, A.; Mellado, B.; Varlamov, S.; et al. Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC). *J. Clin. Oncol.* 2021, 39, 426. [CrossRef]
40. Sjödahl, G.; Lauss, M.; Lövgren, K.; Chebil, G.; Gudjonsson, S.; Veerla, S.; Patschan, O.; Aine, M.; Ferrné, M.; Ringnér, M.; et al. A Molecular Taxonomy for Urothelial Carcinoma. *Clin. Cancer Res.* 2012, 18, 3377–3386. [CrossRef] [PubMed]

41. Challita-Eid, F.M.; Safayev, D.; Yang, P.; An, Z.; Morrison, K.; Hoshiky, T.; Raitano, A.; Nadell, R.; Liu, W.; Lortie, D.R.; et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. *Cancer Res.* 2016, 76, 3003–3013. [CrossRef]

42. Heath, E.J.; Rosenberg, J.E. The biology and clinical relevance of targeting nectin-4 in urothelial carcinoma. *Nat. Rev. Urol.* 2020, 17, 93–103. [CrossRef] [PubMed]

43. Fukao, T.; Koyasu, S. PI3K and negative regulation of TLR signaling. *Trends Immunol.* 2003, 24, 544–548. [CrossRef] [PubMed]

44. Galsky, M.D.; Necchi, A.; Shore, N.D.; Pлимак, E.R.; Jia, C.; Sbar, E.; Moreno, B.H.; Witjes, J.A. KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (mIBC). *J. Clin. Oncol.* 2019, 37, TPS507. [CrossRef]

45. Goldenberg, D.M.; Stein, R.; Sharkey, R.M. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. *Cancers* 2022, 14, 5431.

46. Ocean, A.J.; Starodub, A.N.; Bardia, A.; Vahdat, L.T.; Isakoff, S.J.; Guarino, M.; Messersmith, W.A.; Picozzi, V.J.; Mayer, I.A.; Wegener, W.A.; et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial malignancies: Safety and pharmacokinetics. *Cancer* 2017, 123, 3843–3854. [CrossRef]

47. Yu, E.Y.; Kang, V.; Walken, L.N.; Galsky, M.D. SGNTUC-019: Phase II basket study of tucatinib (TUC) and trastuzumab (Tras) in HER2-positive patients with locally advanced or metastatic urothelial carcinoma (MiBC) who have previously received or refused cisplatin-based chemotherapy. *J. Clin. Oncol.* Off. J. Am. Soc. Clin. Oncol. 2021, 39, 506.

48. Chou, J.; Trepka, K.; Sjöström, M.; Egusa, E.A.; Chu, C.E.; Zhu, J.; Chan, E.; Gibb, E.; Badura, M.L.; Contreras-Sanz, A.; et al. TROP2 expression across molecular subtypes of urothelial carcinoma and Enfortumab Vedotin-resistant cells. *Eur. Urol. Oncol.* 2022. [CrossRef]

49. Yan, M.; Schwaederle, M.; Arguello, D.; Millis, S.Z.; Gatalica, Z.; Kurzrock, R. HER2 expression status in diverse cancers: Review of results from 37,992 patients. *Cancer patients. Cancer* 2015, 34, 157–164. [CrossRef] [PubMed]

50. Choudhury, N.J.; Campanile, A.; Antic, T.; Yap, K.L.; Fitzpatrick, C.A.; Wade, J.L.; Karrison, T.; Stadler, W.M.; Nakamura, Y.; O’Donnell, P.H. Aftatinib in Platinum-Refactory Metastatic Urothelial Patients in Patients with ERBB Alterations. *J. Clin. Oncol.* 2016, 34, 2165–2171. [CrossRef]

51. Grivas, P.; Morales-Barrera, R.; Sridhar, S.S.; Loriot, Y.; Van Der Heijden, M.S.; Galsky, M.D.; Baxter, D.; Khaled, A.H.; Hug, B.A. A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer. *J. Clin. Oncol.* 2021, 39, TPS499. [CrossRef]

52. Mariathasan, S.; Turley, S.J.; Nickles, D.; Castiglioni, A.; Yuen, K.; Wang, Y.; Kadel, E.E.; III; Koeppen, H.; Astarita, J.L.; Cubas, R.; et al. TGFβ1 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. *Nature* 2018, 554, 544–548. [CrossRef]

53. Lind, H.; Gameiro, S.; Jochems, C.; Donahue, R.N.; Strauss, J.; Gulley, J.L.; Palena, C.; Schlom, J. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: Status of preclinical and clinical advances. *J. Immunothe. Cancer* 2019, 8, e00433. [CrossRef] [PubMed]

54. Grivas, P.; Morales-Barrera, R.; Sridhar, S.S.; Loriot, Y.; Van Der Heijden, M.S.; Galsky, M.D.; Baxter, D.; Khaled, A.H.; Hug, B.A. A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer. *J. Clin. Oncol.* 2021, 39, TPS501. [CrossRef]

55. Rascio, F.; Spadaccino, F.; Rocchetti, M.; Castellano, G.; Stallone, G.; Netti, G.; Ranieri, E. The Pathogenic Role of PI3K/akt Pathway in Cancer Onset and Drug Resistance: An Updated Review. *Cancers* 2021, 13, 3949. [CrossRef]

56. Fukao, T.; Koyasu, S. PI3K and negative regulation of TLR signaling. *Trends Immunol.* 2003, 24, 358–363. [CrossRef]

57. López-Knowles, E.; Hernández, S.; Malats, N.; Kogevinas, M.; Lloreta, J.; Carrato, A.; Tardón, A.; Serra, C.; Real, F.X. EPICuro Study Group Investigators PIK3CA Mutations Are an Early Genetic Alteration Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors. *Cancer Res.* 2006, 66, 7401–7404. [CrossRef]

58. Seront, E.; Rottey, S.; Sautois, B.; Kerger, J.; D’Hondt, L.; Verschaeve, V.; Canon, J.-L.; Dophie, C.; Vandenbulcke, J.; Wenhem, N.; et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: Clinical activity, molecular response, and biomarkers. *Ann. Oncol.* 2012, 23, 2663–2670. [CrossRef]

59. Iyer, G.; Hanrahan, A.J.; Milowsky, M.I.; Al-Ahmadi, H.; Scott, S.N.; Janakiraman, M.; Pirun, M.; Sander, C.; Socci, N.D.; Ostrovnyana, I.; et al. Genome Sequencing Identifies a Basis for Everolimus Sensitivity. *Science* 2012, 338, 221. [CrossRef] [PubMed]

60. Gerullis, H.; Eimer, C.; Ecke, T.; Georgas, E.; Freitas, C.; Kastenholz, S.; Arndt, C.; Heusch, C.; Otto, T. A phase II trial of tremelimumab in second-line metastatic urothelial cancer. *Med. Oncol.* 2012, 29, 2870–2876. [CrossRef] [PubMed]

61. McPherson, V.; Bs, B.R.; Bs, A.B.; Bs, S.N.S.; Bs, M.E.B.; Garcia-Grossman, I.R.; Bs, A.M.R.; McCoy, A.S.; Kim, P.H.; Al-Ahmadi, H.; et al. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. *Cancer* 2020, 126, 4532–4544. [CrossRef] [PubMed]
62. Bellmunt, J.; Lalani, A.-K.A.; Jacobus, S.; Wankowicz, S.; Polacek, L.; Takeda, D.Y.; Harshman, L.C.; Wagle, N.; Moreno, I.; Lundgren, K.; et al. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. *Br. J. Cancer* **2018**, *119*, 707–712. [CrossRef] [PubMed]

63. Hartmann, J.; Haap, M.; Kopp, H.-G.; Lipp, H.-P. Tyrosine Kinase Inhibitors—A Review on Pharmacology, Metabolism and Side Effects. *Curr. Drug Metab.* **2009**, *10*, 470–481. [CrossRef] [PubMed]

64. McCombie, W.R.; McPherson, J.D.; Mardis, E.R. Next-Generation Sequencing Technologies. *Cold Spring Harb. Perspect. Med.* **2019**, *9*, a036798. [CrossRef] [PubMed]